Tracking anti-VEGF use among Medicare Part B beneficiaries
Anti-vascular endothelial growth factor (VEGF) agents—including aflibercept, bevacizumab, and ranibizumab—have ushered in a new era in the treatment of retinal and choroidal neovascularization.